ArticleMedical oncology (Northwood, London, England)2017
Elevated levels of epithelial cell transforming sequence 2 predicts poor prognosis for prostate cancer.
Article in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Research progress of ECT2 and RhoA-related signaling pathways in gynecological tumors.Frontiers in cell and developmental biology · 2025Review
- Transcription factor ETS1‑mediated ECT2 expression promotes the malignant behavior of prostate cancer cells.Oncology letters · 2024Article
- Integrating bioinformatics and machine learning methods to analyze diagnostic biomarkers for HBV-induced hepatocellular carcinoma.Diagnostic pathology · 2024Article
- NetActivity enhances transcriptional signals by combining gene expression into robust gene set activity scores through interpretable autoencoders.Nucleic acids research · 2024Article
- 1,25-Dihydroxyvitamin DBiology · 2024Article
- Increased expression of ECT2 predicts the poor prognosis of breast cancer patients.Experimental hematology & oncology · 2022Article
- Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer.Scientific reports · 2022Article
- Fli-1 Activation through Targeted Promoter Activity Regulation Using a Novel 3', 5'-diprenylated Chalcone Inhibits Growth and Metastasis of Prostate Cancer Cells.International journal of molecular sciences · 2020Article
- Targeting Rac and Cdc42 GEFs in Metastatic Cancer.Frontiers in cell and developmental biology · 2020Review
- ECT2 Increases the stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer.Frontiers in oncology · 2020Article
- Oncogenic Ect2 signaling regulates rRNA synthesis in NSCLC.Small GTPases · 2019Review
- Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy.Oncology letters · 2019Article
- Epithelial cell transforming sequence 2 expression is associated with the progression of laryngeal squamous cell carcinoma.Oncology letters · 2019Article
- Overexpression of ECT2 is a strong poor prognostic factor in ER(+) breast cancer.Molecular and clinical oncology · 2019Article
- High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer.Oncology letters · 2018Article
- Article
- A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.PLoS genetics · 2017Article
- P53 and Protein Phosphorylation Regulate the Oncogenic Role of Epithelial Cell Transforming 2 (ECT2).Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epithelial cell transforming sequence 2 (Ect2) was originally reported as an oncogene that is involved in several types of human cancers. However, little is known about its expression and function in prostate cancer. Immunohistochemical staining for Ect2 was performed on a human tissue microarray. The staining intensity was analyzed in association with clinical pathological parameters such as Gleason score, pathological grade, clinical stage, tumor invasion, lymph node and distant metastasis. Furthermore, we repeated such analysis and investigated the prognostic value of Ect2 using the TCGA (The Cancer Genome Atlas) Dataset. Our immunohistochemical results showed that the expression levels of Ect2 protein were enhanced in human prostate cancer tissues. There existed positive correlations between the expression levels of Ect2 and several clinicopathological parameters, including advanced clinical stage, enhanced tumor invasion and lymph node metastasis. Similarly, we found that the expression levels of Ect2 were positively related to Gleason score, tumor invasion, lymph node metastasis and high distant metastasis in the TCGA Dataset. Kaplan-Meier analysis revealed that lower levels of Ect2 mRNA predicted higher overall survivals and biochemical recurrence (BCR)-free survivals in all patients or non-metastatic patients. Multivariate analysis by Cox regression showed that the expression of Ect2 could be an independent prognostic marker of poor BCR-free survivals. Therefore, levels of Ect2 may serve as a novel marker for the diagnosis or prognosis of prostate cancer.
Indexed as
Identifiers
28012134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.